A Study of NDI 1150-101 in Patients With Solid Tumors
Public ClinicalTrials.gov record NCT05128487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination With Pembrolizumab in Patients With Solid Tumors
Study identification
- NCT ID
- NCT05128487
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Nimbus Saturn, Inc.
- Industry
- Enrollment
- 106 participants
Conditions and interventions
Conditions
Interventions
- NDI-101150 Drug
- Pembrolizumab Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 4, 2021
- Primary completion
- Jan 31, 2025
- Completion
- Apr 30, 2025
- Last update posted
- Nov 24, 2024
2021 – 2025
United States locations
- U.S. sites
- 19
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Honor Health Research Institute | Scottsdale | Arizona | 85258 | — |
| Yale Cancer Center | New Haven | Connecticut | 06520 | — |
| Georgetown University | Washington D.C. | District of Columbia | 20007-2113 | — |
| Ocala Oncology Center | Ocala | Florida | 34474 | — |
| Norton Cancer Institute | Louisville | Kentucky | 40202 | — |
| University of Maryland Greenebaum Comprehensive Cancer Center | Baltimore | Maryland | 21201 | — |
| Henry Ford Cancer | Detroit | Michigan | 48202 | — |
| HealthPartners Cancer Research Center | Saint Paul | Minnesota | 55101 | — |
| Washington University | St Louis | Missouri | 63110 | — |
| Hackensack University | Hackensack | New Jersey | 07601 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Stephenson Cancer Center | Oklahoma City | Oklahoma | 73104 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Center for Oncology and Blood Disorders | Houston | Texas | 77030 | — |
| Oncology Consultants | Houston | Texas | 77030 | — |
| NEXT Oncology | San Antonio | Texas | 78229 | — |
| NEXT Oncology | Fairfax | Virginia | 22031 | — |
| Northwest Medical Specialties | Tacoma | Washington | 98405 | — |
| University of Wisconsin | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05128487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 24, 2024 · Synced Apr 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05128487 live on ClinicalTrials.gov.